Why the study?
Does ticagrelor compared to clopidogrel affect the risk of major bleeding in patients after an acute coronary event in clinical practice?
Does ticagrelor compared to clopidogrel affect the risk of major bleeding in patients after an acute coronary event in clinical practice?
In a real-world observational study of 5116 patients after an acute coronary event, the benefits of ticagrelor over clopidogrel seen in clinical trials may not translate to routine clinical practice.
Answers are grounded in this paper and cite their sources.
Ticagrelor may not outperform clopidogrel in routine ACS care; challenges trial generalizability and leaves real-world effectiveness open.
=0.42). Conclusions This observational study indicates that the apparent benefit of ticagrelor demonstrated in a clinical trial population may not be observed in the broader population encountered in clinical practice. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT02484924.
No takes yet. Share an insight, caveat, or question.
Mullen et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: